Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Lauren Y. Lee; Daniela Hernandez; Trivikram Rajkhowa; Samuel C. Smith; Jayant Ranganathan Raman; Bao Nguyen; Donald Small; Mark Levis

doi:10.1182/blood-2016-10-745133

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis

School of Medicine

Research output: Contribution to journal › Letter › peer-review

104 Scopus citations

Original language	English (US)
Pages (from-to)	257-260
Number of pages	4
Journal	Blood
Volume	129
Issue number	2
DOIs	https://doi.org/10.1182/blood-2016-10-745133
State	Published - Jan 12 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-10-745133

Cite this

@article{bc4905d5e7bf4d28932bb16281c33541,

title = "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor",

author = "Lee, {Lauren Y.} and Daniela Hernandez and Trivikram Rajkhowa and Smith, {Samuel C.} and Raman, {Jayant Ranganathan} and Bao Nguyen and Donald Small and Mark Levis",

note = "Funding Information: Acknowledgment: This work was supported by a grant from the National Institutes of Health, National Cancer Institute (NCI Leukemia Specialized Programs of Research Excellence P50 CA100632). Funding Information: Conflict-of-interest disclosure: M.L. receives research funding from Novartis and Astellas and serves as a consultant for Novartis, Daiichi-Sankyo, Astellas, and Arog. The remaining authors declare no competing financial conflicts.",

year = "2017",

month = jan,

day = "12",

doi = "10.1182/blood-2016-10-745133",

language = "English (US)",

volume = "129",

pages = "257--260",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "2",

}

TY - JOUR

T1 - Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

AU - Lee, Lauren Y.

AU - Hernandez, Daniela

AU - Rajkhowa, Trivikram

AU - Smith, Samuel C.

AU - Raman, Jayant Ranganathan

AU - Nguyen, Bao

AU - Small, Donald

AU - Levis, Mark

N1 - Funding Information: Acknowledgment: This work was supported by a grant from the National Institutes of Health, National Cancer Institute (NCI Leukemia Specialized Programs of Research Excellence P50 CA100632). Funding Information: Conflict-of-interest disclosure: M.L. receives research funding from Novartis and Astellas and serves as a consultant for Novartis, Daiichi-Sankyo, Astellas, and Arog. The remaining authors declare no competing financial conflicts.

PY - 2017/1/12

Y1 - 2017/1/12

UR - http://www.scopus.com/inward/record.url?scp=85020494526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020494526&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-10-745133

DO - 10.1182/blood-2016-10-745133

M3 - Letter

C2 - 27908881

AN - SCOPUS:85020494526

SN - 0006-4971

VL - 129

SP - 257

EP - 260

JO - Blood

JF - Blood

IS - 2

ER -

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this